Becton Dickinson downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs analyst David Roman downgraded Becton Dickinson (BDX) to Neutral from Buy with a price target of $192, down from $256. The company’s forward outlook for organic revenue growth has shifted from 5%-6% two years ago to 3%-4% under current operating dynamics, the analyst tells investors in a research note. The firm says this level of organic growth puts Becton at the low-end of medical technology and implies the market will ascribe a lower valuation to the stock. It admits to getting the stock wrong with a Buy rating.